Position in NVCT
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$234,333
-$4,510 QoQ
Shares Held
30,315
-4.2% QoQ
Ownership
0.114%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bank of New York Mellon Corp holds $4,203,063,863 across 270 Biotechnology names. NVCT ranks #229 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,586,427 | $708,403,098 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
765,411 | $591,387,145 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,679,371 | $317,485,079 | |
| 4 | INSM |
INSMED Inc
|
1,262,749 | $206,484,708 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
491,200 | $162,523,337 | |
| 6 | INCY |
Incyte Corp
|
989,709 | $93,151,403 | |
| 7 | TECH |
BIO-TECHNE Corp
|
1,759,119 | $91,931,549 | |
| 8 | MRNA |
Moderna, Inc.
|
1,691,205 | $85,913,207 |
All Filings in NVCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $234,333 | 30,315 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $238,843 | 31,635 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $168,986 | 28,071 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $203,474 | 27,239 | Shares | Defined | 2025-08-05 | |
| 2024-03-31 | $145,591 | 17,755 | Shares | Defined | 2024-04-25 | |
| 2023-12-31 | $159,710 | 19,150 | Shares | Defined | 2024-01-29 | |
| 2023-09-30 | $246,842 | 19,150 | Shares | Defined | 2023-10-24 | |
| 2023-06-30 | $305,824 | 19,150 | Shares | Defined | 2023-08-03 | |
| No filing history on record for this holder in this stock. | ||||||